NASDAQ:VNDA - Vanda Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Vanda Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $12.08 +0.61 (+5.32 %) (As of 02/26/2020 11:12 AM ET) Add Compare Today's Range$10.10Now: $12.08▼$12.2150-Day Range$11.47MA: $13.91▼$16.8052-Week Range$11.34Now: $12.08▼$20.78Volume388,553 shsAverage Volume469,524 shsMarket Capitalization$644.35 millionP/E Ratio5.42Dividend YieldN/ABeta0.27 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:VNDA Previous Symbol CUSIP92165910 CIK1347178 Webhttp://www.vandapharma.com/ Phone202-734-3400Debt Debt-to-Equity RatioN/A Current Ratio4.67 Quick Ratio4.65Price-To-Earnings Trailing P/E Ratio5.42 Forward P/E Ratio5.59 P/E GrowthN/A Sales & Book Value Annual Sales$193.12 million Price / Sales3.34 Cash Flow$0.55 per share Price / Cash Flow21.90 Book Value$5.25 per share Price / Book2.30Profitability EPS (Most Recent Fiscal Year)$0.48 Net Income$25.20 million Net Margins55.49% Return on Equity38.90% Return on Assets31.81%Miscellaneous Employees270 Outstanding Shares53,340,000Market Cap$644.35 million Next Earnings Date4/29/2020 (Estimated) OptionableOptionable Receive VNDA News and Ratings via Email Sign-up to receive the latest news and ratings for VNDA and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:VNDA Rates by TradingView Vanda Pharmaceuticals (NASDAQ:VNDA) Frequently Asked Questions What is Vanda Pharmaceuticals' stock symbol? Vanda Pharmaceuticals trades on the NASDAQ under the ticker symbol "VNDA." How were Vanda Pharmaceuticals' earnings last quarter? Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) released its quarterly earnings data on Tuesday, February, 25th. The biopharmaceutical company reported $0.08 earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of $0.12 by $0.04. The biopharmaceutical company had revenue of $60.93 million for the quarter, compared to analyst estimates of $59.77 million. Vanda Pharmaceuticals had a return on equity of 38.90% and a net margin of 55.49%. View Vanda Pharmaceuticals' Earnings History. When is Vanda Pharmaceuticals' next earnings date? Vanda Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, April 29th 2020. View Earnings Estimates for Vanda Pharmaceuticals. What guidance has Vanda Pharmaceuticals issued on next quarter's earnings? Vanda Pharmaceuticals issued an update on its FY 2020 After-Hours earnings guidance on Tuesday, February, 25th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $240-260 million, compared to the consensus revenue estimate of $274.55 million. What price target have analysts set for VNDA? 4 brokers have issued 12-month price targets for Vanda Pharmaceuticals' stock. Their forecasts range from $17.00 to $25.00. On average, they anticipate Vanda Pharmaceuticals' share price to reach $19.75 in the next year. This suggests a possible upside of 66.5% from the stock's current price. View Analyst Price Targets for Vanda Pharmaceuticals. What is the consensus analysts' recommendation for Vanda Pharmaceuticals? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vanda Pharmaceuticals in the last year. There are currently 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Vanda Pharmaceuticals. What are Wall Street analysts saying about Vanda Pharmaceuticals stock? Here are some recent quotes from research analysts about Vanda Pharmaceuticals stock: 1. According to Zacks Investment Research, "Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. It is developing important new medicines to improve the lives of patients. It uses new technologies, including genetics & genomics, to inform our drug discovery, our clinical trials, and our commercial positioning of our compounds. The Company has three product candidates in clinical development. It's lead product candidate, iloperidone, is a compound for the treatment of schizophrenia & bipolar disorder & is in a Phase III clinical trial for schizophrenia. It's second product candidate, is a compound for the treatment of insomnia & depression which is currently in a Phase III clinical trial for insomnia. It's third product candidate, is a compound for the treatment of excessive sleepiness & is ready for a Phase II clinical trial. " (2/8/2020) 2. Stifel Nicolaus analysts commented, "We are reiterating our Hold rating and $17 target price on VNDA shares as we continue to see limited upside from these levels given a relatively risky pipeline, for which we believe should only be assigned modest value, and a base business that seems more-or-less fully valued. Overall, the quarter looked good with top and bottom line beats driven by Hetlioz and meaningfully lower R&D spend. With that said, 2019 sales guidance for both Hetlioz and Fanapt remain unchanged, though management did update its cash guidance and expects to end 2019 with more cash than previously guided due to the lower spend throughout the year. As we highlighted in our recent deep dive (link here), we see few upside opportunities and more downside risks over the next 12 months and believe the overhang from the FDA lawsuit/tradipitant chronic safety will likely keep shares relatively range bound, in our view." (7/31/2019) Has Vanda Pharmaceuticals been receiving favorable news coverage? Media coverage about VNDA stock has trended somewhat positive this week, according to InfoTrie. The research firm identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Vanda Pharmaceuticals earned a coverage optimism score of 1.0 on InfoTrie's scale. They also assigned news coverage about the biopharmaceutical company a news buzz of 8.0 out of 10, indicating that recent news coverage is very likely to have an effect on the stock's share price in the next few days. View News Stories for Vanda Pharmaceuticals. Are investors shorting Vanda Pharmaceuticals? Vanda Pharmaceuticals saw a drop in short interest in the month of January. As of January 15th, there was short interest totalling 4,010,000 shares, a drop of 10.3% from the December 31st total of 4,470,000 shares. Based on an average daily trading volume, of 556,300 shares, the short-interest ratio is currently 7.2 days. Approximately 7.8% of the company's shares are sold short. View Vanda Pharmaceuticals' Current Options Chain. Who are some of Vanda Pharmaceuticals' key competitors? Some companies that are related to Vanda Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), EXACT Sciences (EXAS), Alnylam Pharmaceuticals (ALNY), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL). What other stocks do shareholders of Vanda Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Vanda Pharmaceuticals investors own include FibroGen (FGEN), Zogenix (ZGNX), Array Biopharma (ARRY), Sangamo Therapeutics (SGMO), NVIDIA (NVDA), Advanced Micro Devices (AMD), Exelixis (EXEL), Micron Technology (MU), Crispr Therapeutics (CRSP) and ImmunoGen (IMGN). Who are Vanda Pharmaceuticals' key executives? Vanda Pharmaceuticals' management team includes the folowing people: Dr. Mihael H. Polymeropoulos, Founder, Pres, CEO & Director (Age 59)Mr. James Patrick Kelly, Exec. VP, CFO, Treasurer & Sec. (Age 53)Mr. Gunther Birznieks, Sr. VP of Bus. Devel. (Age 50)Mr. Gian Piero Reverberi, Sr. VP & Chief Commercial Officer (Age 53)Mr. Timothy Williams, Sr. VP, Gen. Counsel & Sec. Who are Vanda Pharmaceuticals' major shareholders? Vanda Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include Palo Alto Investors LP (8.48%), Renaissance Technologies LLC (6.47%), State Street Corp (4.75%), Prudential Financial Inc. (2.37%), Acadian Asset Management LLC (1.85%) and Geode Capital Management LLC (1.43%). Company insiders that own Vanda Pharmaceuticals stock include Gian Piero Reverberi, Gunther Birznieks, James Patrick Kelly, Mihael Hristos Polymeropoulos, Richard W Dugan and Timothy Williams. View Institutional Ownership Trends for Vanda Pharmaceuticals. Which major investors are selling Vanda Pharmaceuticals stock? VNDA stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Goldman Sachs Group Inc., FMR LLC, Charles Schwab Investment Management Inc., Rafferty Asset Management LLC, 361 Capital LLC, Pictet Asset Management Ltd. and Palo Alto Investors LP. Company insiders that have sold Vanda Pharmaceuticals company stock in the last year include Gian Piero Reverberi, James Patrick Kelly, Mihael Hristos Polymeropoulos, Richard W Dugan and Timothy Williams. View Insider Buying and Selling for Vanda Pharmaceuticals. Which major investors are buying Vanda Pharmaceuticals stock? VNDA stock was bought by a variety of institutional investors in the last quarter, including Prudential Financial Inc., Emerald Advisers LLC, Emerald Mutual Fund Advisers Trust, Renaissance Technologies LLC, Bank of Montreal Can, Acadian Asset Management LLC, Man Group plc and Panagora Asset Management Inc.. View Insider Buying and Selling for Vanda Pharmaceuticals. How do I buy shares of Vanda Pharmaceuticals? Shares of VNDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Vanda Pharmaceuticals' stock price today? One share of VNDA stock can currently be purchased for approximately $11.86. How big of a company is Vanda Pharmaceuticals? Vanda Pharmaceuticals has a market capitalization of $632.61 million and generates $193.12 million in revenue each year. The biopharmaceutical company earns $25.20 million in net income (profit) each year or $0.48 on an earnings per share basis. Vanda Pharmaceuticals employs 270 workers across the globe.View Additional Information About Vanda Pharmaceuticals. What is Vanda Pharmaceuticals' official website? The official website for Vanda Pharmaceuticals is http://www.vandapharma.com/. How can I contact Vanda Pharmaceuticals? Vanda Pharmaceuticals' mailing address is 2200 PENNSYLVANIA AVENUE NW SUITE 300E, WASHINGTON DC, 20037. The biopharmaceutical company can be reached via phone at 202-734-3400 or via email at [email protected] MarketBeat Community Rating for Vanda Pharmaceuticals (NASDAQ VNDA)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 485 (Vote Outperform)Underperform Votes: 390 (Vote Underperform)Total Votes: 875MarketBeat's community ratings are surveys of what our community members think about Vanda Pharmaceuticals and other stocks. Vote "Outperform" if you believe VNDA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VNDA will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/26/2020 by MarketBeat.com StaffFeatured Article: What is the S&P/TSX Index?
